Vericel (VCEL) Shares Outstanding (2010 - 2026)
Vericel (VCEL) posted Shares Outstanding (Entity) of $51.2 million for Q2 2026, little changed sequentially from $51.0 million in Q1 2026, and up 1.45% YoY from $50.4 million in Q2 2025.
Analysis
Vericel (VCEL) Shares Outstanding (2010 - 2026) Analysis & Trends
Vericel has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $51.2 million in Q2 2026.
- Quarterly Shares Outstanding (Entity) rose 1.45% year-over-year to $51.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $51.2 million (up 1.45% YoY) and the FY2025 annual result came in at $50.6 million, up 2.0% from the prior year.
- Shares Outstanding (Entity) steadied at $51.2 million in Q2 2026 per VCEL's latest filing, from $51.0 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $51.2 million in Q2 2026 and troughed at $47.1 million in Q1 2022.
- A 5-year average of $48.9 million and a median of $48.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) grew 0.8% in 2022, then advanced 3.76% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $47.3 million in 2022, then grew by 1.22% to $47.8 million in 2023, then advanced by 3.76% to $49.6 million in 2024, then climbed by 2.0% to $50.6 million in 2025, then climbed by 1.09% to $51.2 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $51.2 million, $51.0 million, and $50.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 51.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.08 Mn |
| Mar 31, 2026 | 50.77 Mn |
| Dec 31, 2025 | 50.34 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 50.37 Mn |
| Mar 31, 2025 | 49.91 Mn |
| Dec 31, 2024 | 48.85 Mn |
| Sep 30, 2024 | 49.09 Mn |
| Jun 30, 2024 | 48.69 Mn |
| Mar 31, 2024 | 48.14 Mn |
| Dec 31, 2023 | 47.59 Mn |
| Sep 30, 2023 | 47.65 Mn |
| Jun 30, 2023 | 47.57 Mn |
| Mar 31, 2023 | 47.39 Mn |
| Dec 31, 2022 | 47.13 Mn |
| Sep 30, 2022 | 47.18 Mn |
| Jun 30, 2022 | 47.12 Mn |
| Mar 31, 2022 | 46.99 Mn |
| Dec 31, 2021 | 46.47 Mn |
| Sep 30, 2021 | 46.67 Mn |